Two recent events in the hyperlipidemia marketplace foreshadow major changes in the prescription drug treatment of this condition. In June 2001, the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) published new guidelines for cholesterol management in the prevention of coronary heart disease (CHD). Shortly thereafter, in August 2001, cerivastatin (Bayer's Lipobay/ GlaxoSmithKline's Baycol) was withdrawn from the market in the United States, Europe, and Japan following treatment-related deaths.

(Photo: )

These events promise dynamic market changes that will affect all competitors in the hyperlipidemia sector. In response to these events, Decision Resources, Inc., announces the publication of The Hyperlipidemia Drug Market Responds to New Guidelines and the Cerivastatin Withdrawal. This timely report addresses two key questions crucial to the future hyperlipidemia market:

  -- How will the new ATP III guidelines affect medical practice and sales      of lipid-lowering therapies?   -- What does the withdrawal of cerivastatin signal for other statins and      lipid-lowering agents?  

ATP III Guidelines Significantly Redefine the Population at Risk of Developing CHD

The ATP III guidelines introduce several modifications of the ATP II guidelines published in 1993 and significantly redefine the population at risk of developing CHD. The new guidelines use global risk assessment methodologies and incorporate the Framingham risk function to establish an even greater population of primary prevention patients at high risk for CHD. The ATP III guidelines also consider diabetes as a CHD risk equivalent.

Impact of ATP III on Medical Practice

We predict that U.S. medical management of hyperlipidemia as a CHD risk factor will ultimately undergo major changes in response to the 2001 ATP III guidelines. The inclusion of CHD equivalents will expand the population considered at high risk of developing CHD. U.S. physicians interviewed for this report expect that while the use of CHD equivalents in primary prevention patients will be a difficult feature to integrate into current medical practice, the net result is that significantly more patients will receive drug treatment. However, despite this most dramatic change from ATP II, we believe that changes in medical practice will occur unevenly within the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) covered in this report. Our interviewed specialists say that the ATP III's strategies for improving adherence to LDL-lowering therapy will in general facilitate uptake during our 2000-2010 forecast period.

Cerivastatin Is Out -- Who Wins?

On the heels of the ATP III publication, the withdrawal of cerivastatin brought a second wave of change to the hyperlipidemia marketplace. The most significant impact of cerivastatin's withdrawal will be reduced uptake of combination therapies, because the fatalities leading to the withdrawal of this statin were linked to its combined use with the fibrate gemfibrozil (Pfizer's Lopid).

The Hyperlipidemia Drug Market Responds to New Guidelines and the Cerivastatin Withdrawal is a PharmaCurrent report, part of Decision Resources' Pharmacor service.

Decision Resources, Inc., is a world leader in pharmaceutical research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years. Visit the Decision Resources Web site at

   Contact:    Frank Sama, 781.296.2553 (telephone), 781.296.2525 (fax), or    In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone),    +32.2.351.2347 (fax), or    In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone),    +81.3.5401.2617 (fax), or 



AP Archive:

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

Contact: Frank Sama of Decision Resources, Inc., +1-781-296-2553,

New Treatment Approaches for Depression: Will They Be Able to Fend Off Generics?

View Now